244 related articles for article (PubMed ID: 31632390)
1. CD137L-DCs, Potent Immune-Stimulators-History, Characteristics, and Perspectives.
Zeng Q; Zhou Y; Schwarz H
Front Immunol; 2019; 10():2216. PubMed ID: 31632390
[TBL] [Abstract][Full Text] [Related]
2. CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8
Dharmadhikari B; Nickles E; Harfuddin Z; Ishak NDB; Zeng Q; Bertoletti A; Schwarz H
Cancer Immunol Immunother; 2018 Jun; 67(6):893-905. PubMed ID: 29508025
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.
Nickles E; Dharmadhikari B; Yating L; Walsh RJ; Koh LP; Poon M; Tan LK; Wang LZ; Ang Y; Asokumaran Y; Chong WQ; Huang Y; Loh KS; Tay J; Soo R; Koh M; Ho LP; Chan M; Niam M; Soh M; Luah YH; Lim CM; Kaliaperumal N; Au VB; Talib NBSN; Sng R; Connolly JE; Goh BC; Schwarz H
Cancer Immunol Immunother; 2022 Jun; 71(6):1531-1543. PubMed ID: 34661709
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional and functional characterization of CD137L-dendritic cells identifies a novel dendritic cell phenotype.
Harfuddin Z; Dharmadhikari B; Wong SC; Duan K; Poidinger M; Kwajah S; Schwarz H
Sci Rep; 2016 Jul; 6():29712. PubMed ID: 27431276
[TBL] [Abstract][Full Text] [Related]
5. Increased Akt-Driven Glycolysis Is the Basis for the Higher Potency of CD137L-DCs.
Zeng Q; Mallilankaraman K; Schwarz H
Front Immunol; 2019; 10():868. PubMed ID: 31068941
[TBL] [Abstract][Full Text] [Related]
6. Species difference of CD137 ligand signaling in human and murine monocytes.
Tang Q; Jiang D; Shao Z; Martínez Gómez JM; Schwarz H
PLoS One; 2011 Jan; 6(1):e16129. PubMed ID: 21264248
[TBL] [Abstract][Full Text] [Related]
7. CD137 ligand reverse signaling has multiple functions in human dendritic cells during an adaptive immune response.
Lippert U; Zachmann K; Ferrari DM; Schwarz H; Brunner E; Mahbub-Ul Latif AH; Neumann C; Soruri A
Eur J Immunol; 2008 Apr; 38(4):1024-32. PubMed ID: 18395851
[TBL] [Abstract][Full Text] [Related]
8. Regulation of myelopoiesis by CD137L signaling.
Tang Q; Jiang D; Harfuddin Z; Cheng K; Moh MC; Schwarz H
Int Rev Immunol; 2014; 33(6):454-69. PubMed ID: 24941289
[TBL] [Abstract][Full Text] [Related]
9. A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling.
Ju S; Ju S; Ge Y; Qiu H; Lu B; Qiu Y; Fu J; Liu G; Wang Q; Hu Y; Shu Y; Zhang X
Int Immunol; 2009 Oct; 21(10):1135-44. PubMed ID: 19684160
[TBL] [Abstract][Full Text] [Related]
10. Methods for generating the CD137L-DC-EBV-VAX anti-cancer vaccine.
Nickles E; Xia R; Sun R; Schwarz H
Methods Cell Biol; 2024; 183():187-202. PubMed ID: 38548412
[TBL] [Abstract][Full Text] [Related]
11. The Progress of Investigating the CD137-CD137L Axis as a Potential Target for Systemic Lupus Erythematosus.
Mak A; Schwarz H
Cells; 2019 Sep; 8(9):. PubMed ID: 31500130
[TBL] [Abstract][Full Text] [Related]
12. IL-4 blocks TH1-polarizing/inflammatory cytokine gene expression during monocyte-derived dendritic cell differentiation through histone hypoacetylation.
López-Bravo M; Minguito de la Escalera M; Domínguez PM; González-Cintado L; del Fresno C; Martín P; Martínez del Hoyo G; Ardavín C
J Allergy Clin Immunol; 2013 Dec; 132(6):1409-19. PubMed ID: 24139608
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
[TBL] [Abstract][Full Text] [Related]
14. CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses.
Harfuddin Z; Kwajah S; Chong Nyi Sim A; Macary PA; Schwarz H
Oncoimmunology; 2013 Nov; 2(11):e26859. PubMed ID: 24482752
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors.
Prasad M; Ponnalagu S; Zeng Q; Luu K; Lang SM; Wong HY; Cheng MS; Wu M; Mallilankaraman K; Sobota RM; Lim YT; Wang LC; Goh CK; Tay KXJ; Loh KS; Wang CI; Lee WH; Goh BC; Lim CM; Schwarz H
Cancer Immunol Immunother; 2022 Nov; 71(11):2583-2596. PubMed ID: 35299256
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus vaccine therapy with CD137L promotes CD8
Ding J; Jiang N; Zheng Y; Wang J; Fang L; Li H; Yang J; Hu A; Xiao P; Zhang Q; Chai D; Zheng J; Wang G
Pharmacol Res; 2022 Jan; 175():106034. PubMed ID: 34915126
[TBL] [Abstract][Full Text] [Related]
17. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
Santodonato L; D'Agostino G; Nisini R; Mariotti S; Monque DM; Spada M; Lattanzi L; Perrone MP; Andreotti M; Belardelli F; Ferrantini M
J Immunol; 2003 May; 170(10):5195-202. PubMed ID: 12734367
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus induces the differentiation of semi-mature dendritic cells from cord blood monocytes.
Jin YY; Wang X; Du J; Cao RM; Law HK; Wang JJ; Chen TX
Hum Immunol; 2014 Apr; 75(4):306-16. PubMed ID: 24530751
[TBL] [Abstract][Full Text] [Related]
19. Role of the CD137 ligand (CD137L) signaling pathway during Mycobacterium tuberculosis infection.
Martínez Gómez JM; Koh VH; Yan B; Lin W; Ang ML; Rahim SZ; Pethe K; Schwarz H; Alonso S
Immunobiology; 2014 Jan; 219(1):78-86. PubMed ID: 24091276
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells generated from CD34+ progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-alpha are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells.
Ferlazzo G; Klein J; Paliard X; Wei WZ; Galy A
J Immunother; 2000 Jan; 23(1):48-58. PubMed ID: 10687137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
